Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD trial for sabirnetug (ACU193), a drug targeting early Alzheimer's disease, did not meet the primary endpoint of slowing cognitive and functional decline compared to placebo. The trial also failed key secondary endpoints, although the drug was generally well tolerated and showed significant amyloid plaque reduction. Based on these results, Acumen will stop developing sabirnetug, including the trial's extension phase, and will explore strategic options while conserving cash. The company remains hopeful for future Alzheimer's treatments and appreciates the efforts of patients and staff involved.
Acumen Pharmaceuticals' Phase 2 trial results provide context for readers following developments in early Alzheimer's disease treatments. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 30, 2026 16:51 WIB: out of 150 priced US health stocks, 73 rose and 70 fell. Notable movers include BTSG at USD 64.58 with a 7.24% increase and 90% buy orders, CTXR at USD 0.60 with a 6.32% rise but 100% sell orders, and TWST at USD 163.79 down 5.57% with 64% buy orders.
FirstCash Holdings reported a 28% year-over-year decline in operating income for its American First Finance segment and a 15% drop in lease and loan originations for Q3 2026. This led to a 14.75% stock price decline on October 22, 2026. The Law Offic...
Oxford Square Capital Corp. announced its financial results for Q3 2026, reporting a net asset value (NAV) per share of $1.21, down from $1.29 in Q2. The company declared monthly dividends of $0.015 per share for January, February, and March 2027. Ne...
As Halloween approaches, MADD Canada warns against impaired driving caused by alcohol, cannabis, or drugs, which leads to hundreds of deaths and thousands of injuries annually in Canada. The organization urges people to plan safe transportation if co...
MADD Canada warns Canadians to avoid impaired driving during Halloween, emphasizing the risks of alcohol, cannabis, and drug-related crashes that cause deaths and injuries annually. The organization urges people to plan safe rides, watch for children...
Jupiter Lend, a Solana-based lending protocol, is temporarily restricting some withdrawals due to reduced available liquidity. At one point, only about 7,900 USDC was immediately accessible from a vault holding roughly $419.6 million. The protocol at...
